Specifically in melanoma, high dosage of arm- or chromosome-level SCNAs were associated with poorer response to anti-CTLA-4 in a retrospective analysis [148], one such example being gains in chromosome 7 that are accompanied by poor lymphocyte infiltrate and aberrant neutrophil activation [149]. This evidence concerns the gene CTLA4 and melanoma.